In this issue:
Cell therapy in Chagas cardiomyopathy
Influence of β-blockers on HR reduction by ivabradine
SHIFTing our thinking about digoxin
HR and outcomes in chronic HF patients
Testosterone supplementation in HF
NT-proBNP and patient characteristics/outcomes in diastolic HF
FT011 in experimental diabetic cardiomyopathy
Lixivaptan in HF outpatients with volume overload
Warfarin vs. aspirin in HF with sinus rhythm
SERCA2a gene therapy restores microRNA-1 expression
Please login below to download this issue (PDF)